About this Research Topic
Hematological malignancies represent defying clinical conditions affecting either the lymphoid or the myeloid lineages. Targeted therapy research is developing rapidly from bench to bedside based on the continually up-dated disease molecular understanding and growing novel target identifications in malignancy. Patient survival expectations and clinical outcomes are closely associated with the development of precision treatments. For example, acute myeloid leukemia (AML) is a group of myeloid malignancies characterized by high heterogeneity in clinical courses and therapy responses. The emergence of new targeted agents such as FLT3, BCL2 inhibitors, or immune checkpoint blockade (ICB) therapy has significantly improved the survival of a subtype of AML. In addition, inspired by the promising outcomes of CAR-T therapy in certain malignancies, various new immunotherapy technologies are emerging rapidly based on neoantigens. Nevertheless, the lack of ideal targets or neoantigens seems to be one of the major stumbling blocks in the precision immunotherapy of most hematological malignancies. Currently, developed technological innovations have driven the identification of more and more malignant disease-specific novel molecules, or neoantigens, that arise as diagnostic biomarkers and therapeutic targets. Thus, precision-targeted immunotherapy is developing as one of the most promising approaches in the battle against these hematological malignant diseases. There is no doubt that the development of novel precision diagnoses and therapeutic approaches against these novel targets or neoantigens will outline the prospective clinical applications in the future.
Given the significant clinical outcomes of novel target-based immunotherapy and uncovered mechanism understanding in hematological malignancies, the research topic welcomes studies involved in the latest developments in novel target or neoantigen discoveries and utilizations, including small chemical molecular immunomodulatory drug development, vaccines, antibodies, and cell therapies, from basic preclinical research to translational studies in hematological malignancies. The main goal of this research topic is to draw a clear framework within which we can see the steps that should be taken to establish and maintain effective anti-malignancy immune responses based on novel target or neoantigen-associated immunotherapeutic approaches, which are crucial for interpreting hematological malignancy clinical outcomes.
The research topic welcomes submissions of original research articles, brief research reports, clinical cases, perspectives, mini-reviews, and reviews concerning hematological malignancies. Topics include, but are not limited to:
1). Novel target or neoantigen screening and discovery method development;
2). Novel target or neoantigen-based malignancy diagnosis;
3). Novel small chemical molecular immunomodulatory drug development;
4). Novel vaccine, antibody development, and cell immunotherapy;
5). Immune escape or resistance mechanisms.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Given the significant clinical outcomes of novel target-based immunotherapy and uncovered mechanism understanding in hematological malignancies, the research topic welcomes studies involved in the latest developments in novel target or neoantigen discoveries and utilizations, including small chemical molecular immunomodulatory drug development, vaccines, antibodies, and cell therapies, from basic preclinical research to translational studies in hematological malignancies. The main goal of this research topic is to draw a clear framework within which we can see the steps that should be taken to establish and maintain effective anti-malignancy immune responses based on novel target or neoantigen-associated immunotherapeutic approaches, which are crucial for interpreting hematological malignancy clinical outcomes.
The research topic welcomes submissions of original research articles, brief research reports, clinical cases, perspectives, mini-reviews, and reviews concerning hematological malignancies. Topics include, but are not limited to:
1). Novel target or neoantigen screening and discovery method development;
2). Novel target or neoantigen-based malignancy diagnosis;
3). Novel small chemical molecular immunomodulatory drug development;
4). Novel vaccine, antibody development, and cell immunotherapy;
5). Immune escape or resistance mechanisms.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: Neoantigen, Cancer Immunotherapy, hematological malignancy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
